Business
MicroBlateT Flex clinical study
MicroBlateT Flex clinical study.
About this update from Creo Medical Group Plc
[{"type":"text","content":"\n \n \n \n \n \n Creo Medical Group plc\n \n \n (\"Creo\" the \"Company\" or the \"Group\")\n \n \n \n \n \n \n MicroBlate\n \n \n ™\n \n Flex\n \n \n \n clinical study in lung lesion microwave ablation\n \n \n \n \n Multicentre observational study representing first in human use of the device for\n \n \n \n \n soft tissue lung lesions\n \n \n \n \n \n \n Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of surgical endoscopy, announces a multi-site clinical study (the \"Study\") to evaluate the safety and feasibility of MicroBlate™ Flex, Creo's bronchoscopic microwave ablation device, for the treatment of lung lesions.\n \n \n \n \n \n \n MicroBlate\n \n ™ Flex is a new soft tissue ablation device, designed with the aim of being able to ablate nodules and tumours in several tissue types using the highest frequency MW energy used for tumour ablation. Lung cancer is the most common cancer in men and the second most common cancer in women[1], and treatment options are currently sub optimal and typically involve chemotherapy, radiation therapy, surgery or a combination thereof. The size and flexibility of MicroBlate™ Flex offer patients the prospect of a significantly less invasive procedure when treating lung tumours than alternatives. MicroBlate™ Flex also has potential to be used to treat a number of other conditions, where a small diameter flexible device enables access into otherwise inaccessible regions of the body.\n \n \n \n \n \n The Study is the first of a number of planned studies designed by Creo, in conjunction with Kamaptive partners, in respect of Creo's suite of ablation devices during 2023 and beyond. The S\n tudy will initially take place in the UK, and may expand to up to a total of six sites across Europe, with the potential to expand into the United States.\n \n \n \n \n \n As principal investigator, Pallav L Shah, MD, of the Royal Brompton and Harefield NHS Foundation Trust, has commenced the process to recruit patients to undergo treatment. The\n patients recruited will represent the first in-human cases for Creo's MicroBlate™ Flex device and\n will have regular follow-up assessments for twelve months post-procedure to monitor their progress. The first case is expected to take place during Q2 2023.\n \n \n \n \n \n Ful...